What do systematic reviews say?

Deferasirox vs deferiprone (DFO)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  0.96 [0.06, 15.42]
  2 studies · 240 participants
  Very low

Hydroxyurea vs placebo

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 193 participants
  Low

Angiotensin‐converting enzyme inhibitors vs placebo

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Meglitinides vs sulphonylureas

The review found no eligible studies for this question.

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SGLT‐2 inhibitors vs sulphonylureas

The review found no eligible studies for this question.

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

GLP‐1 analogues inhibitors vs sulphonylureas

The review found no eligible studies for this question.

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Insulin analogues vs biphasic insulin

It is very uncertain whether insulin analogues changes all‐cause mortality compared with biphasic insulin (very low certainty).

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  RR 3.02 [0.12, 73.53]
  1 study · 263 participants
  Very low

Telemedicine vs usual care

The review found no eligible studies for this question.

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DPP‐4 inhibitors vs sulphonylureas

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 2426 participants
  Moderate

Patient education vs usual care

The review found no eligible studies for this question.

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Drug dosage reduction vs usual care

The review found no eligible studies for this question.

• Interventions for people with type 2 diabetes mellitus fasting during Ramadan 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in all‐cause mortality (low certainty).

• Social network interventions to support cardiac rehabilitation and secondary prevention in the management of people… 2023 · Cochrane Headline outcomes only
  RR 0.75 [0.49, 1.13]
  6 studies · 3093 participants
  Low

Sildenafil vs Placebo or no active treatment

Sildenafil citrate showed no clear difference in all‐cause mortality compared with placebo or no therapy (moderate certainty).

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  RR 1.01 [0.8, 1.27]
  5 studies · 516 participants
  Moderate

Sildenafil vs IV nitroglycerin

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Low

Tadalafil vs Placebo or no active treatment

Tadalafil showed no clear difference in all‐cause mortality compared with placebo or no therapy (low certainty).

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  RR 0.2 [0.02, 1.6]
  1 study · 87 participants
  Low

Nitroglycerin vs Placebo or no active treatment

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Low

Summary of findings table ‐ Remifentanil vs diazepam

The review found no eligible studies for this question.

• Perioperative pharmacological interventions for fetal immobilisation during fetal surgery and invasive procedures 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Heparin vs pentasaccharide

• Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 198 participants
  Very low

Heparin started before vs after the surgical procedure

• Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Very low

IPC plus pharmacological prophylaxis vs mechanical prophylaxis alone

• Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 150 participants
  Low